MHC class I antigens and immune surveillance in transformed cells.
about
Immune responses to human cancer stem-like cells/cancer-initiating cellsProgress in immunotherapy for non-small cell lung cancerThe Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A ReviewA transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasisChemical metabolic inhibitors for the treatment of blood-borne cancersCancer immunotherapy: how low-level ionizing radiation can play a key role.Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.Quantification of HLA class I molecules on renal cell carcinoma using Edman degradationEmpirical evaluations of analytical issues arising from predicting HLA alleles using multiple SNPs.αβT cell receptors expressed by CD4(-)CD8αβ(-) intraepithelial T cells drive their fate into a unique lineage with unusual MHC reactivities.MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroDifferential genome-wide profiling of tandem 3' UTRs among human breast cancer and normal cells by high-throughput sequencing.MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells.Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteersLate pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case reportProteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer.Cancer treatment: the combination of vaccination with other therapies.Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.Relationship between major histocompatibility complex class I expression and prognosis in canine mammary gland tumorsNovel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.Targeting HLA class I expression to increase tumor immunogenicity.Adoptive T-cell transfer in melanoma.Epigenetics of melanoma: implications for immune-based therapies.Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype.Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study.Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.CancerPDF: A repository of cancer-associated peptidome found in human biofluids.Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture.Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth.HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer.Protein Kinase C-θ (PKC-θ) in Natural Killer Cell Function and Anti-Tumor ImmunityCoordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms.Aggressive Behavior in Silent Subtype III Pituitary Adenomas May Depend on Suppression of Local Immune Response: A Whole Transcriptome Analysis.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance.
P2860
Q26781794-BD154A82-D052-4F86-99B2-C85E12313622Q26865725-B136D39B-3275-4209-A92F-A9FDD850F8F5Q28080338-ABCF3D70-0798-4BC6-975D-632FB52468BBQ28289791-062AEF92-CB49-4BE8-954A-89AD2183BBDAQ28822335-6B66951B-BB69-49D9-AE7C-0A4C8B7BCC3EQ30235014-24DE8B9A-1B18-456E-84A0-1296BEF6396AQ33724135-E808ED25-BA81-4453-8C9C-F9EBF0B6B2A2Q33798689-9C693577-11C6-472D-9E07-4CAEF834816EQ33881593-593AC285-C5AE-4F6D-99B1-8040C0DC8EECQ34082153-01CD41F3-A3FB-47C8-984D-15374B792550Q34615021-C731BFE5-59FC-4421-BBD6-43072294C142Q34867927-6EB567DB-2125-4262-A660-2D32C58D142AQ35201839-9CDD6E65-76CF-4461-8F33-5898CA2931C9Q36214486-00AAA506-CACE-4E0E-A303-470D4A118089Q36608959-699641C2-ABBE-4BE3-B851-F642095342FFQ36847539-094B768F-E328-4794-A487-5F5541F66A6EQ37089001-C175E28A-BED0-43A0-9952-57101821A59CQ37590119-719C6863-BFC2-40FA-8C5D-03C36581B6F9Q37618172-D49E7101-910D-4097-BDE5-5C801BE77B18Q37902639-D6BF24F7-FA2C-4641-930C-5A3DA594967FQ37981721-CF8C3B31-4F32-4834-9F74-6C6487F84591Q38068968-BE620887-E125-4CFC-A77E-151FAD56BB8BQ38148588-91EF72F9-F799-4437-9C7E-B7BBFF2CA752Q38282541-9D23453A-EC24-4A6A-B25B-F9269A9120D2Q38689030-A7CCE3C8-2420-4194-9D9C-E603925B5946Q38732479-FA85A07B-59AA-416A-A223-83E8916CA77EQ38803215-D2759D50-B7F2-45BD-87D6-440891BE239DQ38980455-B9C95BE4-3F15-40A8-836B-96FE1C746851Q39137410-616AF51C-918E-4542-9B3E-8B0CF618B1ECQ39164068-510060B0-BEB0-4801-886C-943CD7BE3745Q39247530-C79EA4F6-2BDB-43FC-B042-1565D42DE990Q39781532-F8D97913-788A-4930-9004-133796BF6602Q41592674-6448F89F-0FA9-4215-B838-CD3DB1E09F61Q41984556-4F11E9CC-D598-4543-AF78-15A65FDD51B8Q42440049-7A6A192B-8DF4-4AB5-AB31-6BAFCD23A617Q47704805-55D5431D-BB2F-40F1-B41F-C03852390C9FQ47784194-4CADDA67-766E-4CFF-8BAE-34272E58BE1AQ48156858-E25162BA-7A63-4215-A90A-891C6F57023DQ50054492-3BEE89DE-44EA-4F3F-84A5-567F6D6E1042Q53807444-9C56D549-5F0E-4F1B-8832-343D47797C0E
P2860
MHC class I antigens and immune surveillance in transformed cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
MHC class I antigens and immune surveillance in transformed cells.
@ast
MHC class I antigens and immune surveillance in transformed cells.
@en
type
label
MHC class I antigens and immune surveillance in transformed cells.
@ast
MHC class I antigens and immune surveillance in transformed cells.
@en
prefLabel
MHC class I antigens and immune surveillance in transformed cells.
@ast
MHC class I antigens and immune surveillance in transformed cells.
@en
P2093
P1476
MHC class I antigens and immune surveillance in transformed cells
@en
P2093
Federico Garrido
Francisco Ruiz-Cabello
Miguel Angel Lopez-Nevot
Natalia Aptsiauri
P304
P356
10.1016/S0074-7696(07)56005-5
P577
2007-01-01T00:00:00Z